Back
Capricor faces class action over Deramiocel FDA disclosure claims

Capricor faces class action over Deramiocel FDA disclosure claims

Proposed shareholder suits target investors who bought Capricor securities from Dec. 17, 2025 to July 26, 2026, alleging the company misled the market about statistical-analysis changes and resulting FDA approval risk for Deramiocel.

Fact Check
The claim is fully corroborated. The Bragar Eagel & Squire GlobeNewswire release directly confirms the firm is investigating Capricor for potential securities-law violations tied to the FDA's statement that the therapy did not meet Phase 3 endpoints and a 64.5% share plunge. The Hagens Berman release corroborates the FDA briefing document, negative endpoint findings, and the stock crash. Independent BioSpace reporting confirms the FDA advisory committee's 9-3 vote against deramiocel and the FDA's dispute of Capricor's Phase 3 success claims. All components of the claim—law firm investigations, FDA briefing, negative advisory-panel vote, share declines, and the therapy Deramiocel—are substantiated across primary and independent sources.
    Reference: 123
Summary

Capricor Therapeutics is facing shareholder class-action litigation alleging it misled investors about regulatory risks tied to Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy. The complaints allege Capricor changed the pre-specified statistical analysis plan for Deramiocel data, resubmitted its biologics license application without prior FDA agreement to those changes, and exposed the filing to a significant risk that the agency would find the evidence insufficient to support approval. The claims followed FDA briefing documents released July 27, 2026 and a July 29 advisory-committee vote of 9-3 against the available evidence supporting efficacy for DMD-associated cardiomyopathy. Capricor has said the vote was non-binding, addressed a narrower indication than it proposed, and did not address Deramiocel’s overall benefit-risk profile, while the company remained focused on its August 22, 2026 PDUFA target action date. One filed case said investors had 60 days from the notice date to seek lead-plaintiff status, and a separate notice set a September 28, 2026 lead-plaintiff deadline.

Terms & Concepts
  • statistical analysis plan: A prespecified document that sets out how clinical-trial data will be analyzed before results are reviewed.
  • biologics license application: A formal submission seeking FDA approval to market a biologic product.
  • lead plaintiff: An investor appointed by the court to represent the proposed class in a securities lawsuit.